Ocugen, Inc. (OCGN)

Ocugen to Participate in Upcoming September Investor and Industry Conferences

Brokerages Set Ocugen, Inc. (NASDAQ:OCGN) Price Target at $9.50

Ocugen Targets 2027 BLA Filings as Gene Therapy Programs Near Key Readouts

Ocugen's Q2 Earnings Miss Estimates as R&D Costs Rise, Stock Falls

Ocugen Q2 Earnings Call Highlights

Ocugen, Inc. (OCGN) Q2 2026 Earnings Call Transcript

Ocugen (OCGN) Reports Q2 Loss, Beats Revenue Estimates

Ocugen Provides Business Update with Second Quarter 2026 Financial Results

Ocugen to Participate in Upcoming August Investor Conferences

Ocugen Announces that the U.S. Food and Drug Administration Has Granted OCU410 Regenerative Medicine Advanced Therapy (RMAT) Designation for Treatment of Geographic Atrophy, Secondary to Dry Age-Related Macular Degeneration

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen to Host Conference Call on Thursday, August 6 at 8:30 A.M. ET to Discuss Business Updates and Second Quarter 2026 Financial Results

Ocugen, Inc. Announces Binding Term Sheet with Roots Pharmaceutical to License OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North Africa

Ocugen Eyes 3 Retinal Gene Therapy Filings as Late-Stage Pipeline Advances

Ocugen to Participate in Upcoming July Industry Conferences

Ocugen to Participate in Upcoming July Industry Conferences

Why Is Ocugen (OCGN) Down 10.7% Since Last Earnings Report?

Ocugen's Gene-Agnostic Eye Therapies Could Reshape Late-Stage Care

Is OCGN Stock Worth the Risk Ahead of 2026-27 Eye Gene Therapy Data?

OCGN's Catalyst Calendar for Trial Data and Filings Through 2028